Pulling SEC filings + quote and writing the call…

MediWound Ltd.
Next earnings Aug 12, 2026 · consensus $-0.78 EPS, $2.64M rev
Mixed signals in the latest filings.
MediWound Ltd. shows limited reported revenue.
On these fundamentals, MDWD screens as SELL on the SEC figures.
Is MDWD a buy? The one-page verdict, explained →
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
No income data filed.
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001593984, latest 4 filed 2026-06-04) · EODHD · as of 7/4/2026, 10:37:28 PM.
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:37 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 6 open-market buys · 0 sales
| 2026-06-03 | SHAMIR NACHUM Director | Buy | 175.00 @ $13.98 | $2.45K |
| 2026-06-03 | SHAMIR NACHUM Director | Buy | 5.83K @ $14.00 | $81.5K |
| 2026-06-01 | Fox David Morton Director | Buy | 1.73K @ $14.23 | $24.6K |
| 2026-06-01 | Fox David Morton Director | Buy | 10.00 @ $14.23 | $142.30 |
| 2026-06-01 | Fox David Morton Director | Buy | 1.80K @ $14.00 | $25.1K |
| 2026-05-29 | Rubinstein Samuel Director | Buy | 150.00 @ $14.33 | $2.15K |
| ARK Investment Management | 130K sh | $2.09M |
As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →
1195 tracked peers · median